WB Stallions

Main Menu

  • Home
  • Planned matings
  • Purebred horses
  • Reproduction
  • Successful foaling
  • Breeding costs

WB Stallions

Header Banner

WB Stallions

  • Home
  • Planned matings
  • Purebred horses
  • Reproduction
  • Successful foaling
  • Breeding costs
Reproduction
Home›Reproduction›Lower antibody efficacy for omicron compared to delta: Japanese study

Lower antibody efficacy for omicron compared to delta: Japanese study

By Linda J. Sullivan
January 27, 2022
0
0

This electron microscope photo shows the omicron variant of the coronavirus successfully isolated at the National Institute of Infectious Diseases. (Photo courtesy of the National Institute of Infectious Diseases.)

TOKYO — Antibody drugs that help prevent a virus from sticking to cells may be less effective for the omicron variant of the coronavirus than for the delta strain, according to a study by a team from the Institute of Medical Sciences in Tokyo. the University of Tokyo and the National Institute of Infectious Diseases. find.

At the same time, the researchers found that antiviral drugs that prevent viral reproduction inside the body showed roughly the same effectiveness for both variants. Their findings were published online in the January 26 edition of the New England Journal of Medicine.

The team led by Yoshihiro Kawaoka, a project professor of virology at the University of Tokyo, used cultured cells to test the effectiveness of existing drugs to treat COVID-19. The antibodies prevent the virus from sticking to cells and help prevent viral reproduction, and in Japan the antibody cocktail Ronapreve and the neutralizing antibody sotrovimab (brand name Xevudy) have been approved.

The result showed that the effectiveness of Ronapreve in preventing omicron from reproducing was 1/5,261 or less compared to its effectiveness against the delta variant. Sotrovimab was about two-thirds less effective against omicron than delta.

Antiviral drugs, on the other hand, interfere with the function of an enzyme that the virus needs to multiply once it enters the body. The oral drug molnupiravir is one such drug recently approved in Japan.

In the experiment, molnupiravir and intravenously administered remdesivir (also approved in Japan) would have prevented the reproduction of delta and omicron about equally.

As omicron spreads rapidly around the world, a selection of effective drugs is essential to ease the pressure on medical care providers. Kawaoka told the Mainichi Shimbun: “Regarding the antibodies, we believe that it has become difficult for the antibody agent to bind to the spike protein on the surface of the virus due to the multiple mutations of the omicron variant. There is a need to carefully determine efficacy in clinical settings.”

(Japanese original by Ayumu Iwasaki, Department of Science and Environmental News)

Related posts:

  1. Look for Public Enemy # 1 during the mid-season spotting
  2. European Parliament adopts resolution demanding the right to a safe abortion
  3. Cutting funding could limit reproductive care accessible to low-income women, advocates say
  4. The Big Easel – Emerald, Australia

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • March 2021

Categories

  • Breeding costs
  • Planned matings
  • Purebred horses
  • Reproduction
  • Successful foaling

Recent Posts

  • Do you have $5,000? These 3 growth stocks are trading near their 52-week lows
  • The brilliant Al Ghadeer wins the Al Rayyan Cup in France
  • Will a loan on my 401(k) affect my mortgage?
  • Deauville’s classic debut for Blue Diamond Stud
  • More teachers are embracing reproductive technologies
  • Privacy Policy
  • Terms and Conditions